FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4294892020> ?p ?o ?g. }

• W4294892020 endingPage "284" @default.
• W4294892020 startingPage "276" @default.
• W4294892020 abstract "PURPOSE The adjunctive use of intraoperative molecular imaging (IMI) is gaining acceptance as a potential means to improve outcomes for surgical resection of targetable tumors. This confirmatory study examined the use of pafolacianine for real-time detection of folate receptor–positive ovarian cancer. METHODS This phase III, open-label, 11-center study included subjects with known or suspected ovarian cancer, scheduled to undergo cytoreductive surgery. The objectives were to confirm safety and efficacy of pafolacianine (0.025 mg/kg IV), given ≥ 1 hour before intraoperative near-infrared imaging to detect macroscopic lesions not detected by palpation and normal white light. RESULTS From March 2018 through April 2020, 150 patients received a single infusion of pafolacianine (safety analysis set); 109 patients with folate receptor–positive ovarian cancer comprised the full analysis set for efficacy. In 33.0% of patients (95% CI, 24.3 to 42.7; P < .001), pafolacianine with near-infrared imaging identified additional cancer on tissue not planned for resection and not detected by white light assessment and palpation, exceeding the prespecified threshold of 10%. Among patients who underwent interval debulking surgery, the rate was 39.7% (95% CI, 27.0 to 53.4; P < .001). The sensitivity to detect ovarian cancer was 83%, and the patient false-positive rate was 24.8%. Investigators reported achieving complete R0 resection in 62.4% (68 of 109) of patients. Drug-related adverse events were reported by 30% of patients (45 of 150) and most commonly included nausea, vomiting, and abdominal pain. No drug-related serious adverse events or deaths were reported. CONCLUSION This phase III study of pafolacianine met its primary efficacy end point, identifying additional cancers not otherwise identified or planned for resection. Pafolacianine may offer an important real-time adjunct to current surgical approaches for ovarian cancer." @default.
• W4294892020 created "2022-09-07" @default.
• W4294892020 creator A5001186013 @default.
• W4294892020 creator A5007373031 @default.
• W4294892020 creator A5012009133 @default.
• W4294892020 creator A5028075025 @default.
• W4294892020 creator A5034012906 @default.
• W4294892020 creator A5039245628 @default.
• W4294892020 creator A5039736511 @default.
• W4294892020 creator A5044655732 @default.
• W4294892020 creator A5062258178 @default.
• W4294892020 creator A5071527937 @default.
• W4294892020 creator A5078818153 @default.
• W4294892020 creator A5080149644 @default.
• W4294892020 creator A5080722354 @default.
• W4294892020 creator A5087302565 @default.
• W4294892020 date "2023-01-10" @default.
• W4294892020 modified "2023-10-12" @default.
• W4294892020 title "A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor–Positive Ovarian Cancer (Study 006)" @default.
• W4294892020 cites W1570518064 @default.
• W4294892020 cites W1635858395 @default.
• W4294892020 cites W1918904712 @default.
• W4294892020 cites W1925331890 @default.
• W4294892020 cites W1964736695 @default.
• W4294892020 cites W1985650168 @default.
• W4294892020 cites W1999947358 @default.
• W4294892020 cites W2049490668 @default.
• W4294892020 cites W2060459188 @default.
• W4294892020 cites W2112579958 @default.
• W4294892020 cites W2170192029 @default.
• W4294892020 cites W2245672559 @default.
• W4294892020 cites W2313984291 @default.
• W4294892020 cites W2316581203 @default.
• W4294892020 cites W2421919823 @default.
• W4294892020 cites W2791893228 @default.
• W4294892020 cites W2800574178 @default.
• W4294892020 cites W2897430921 @default.
• W4294892020 cites W2951714360 @default.
• W4294892020 cites W2964841427 @default.
• W4294892020 cites W2975141952 @default.
• W4294892020 cites W2994977341 @default.
• W4294892020 cites W2999103821 @default.
• W4294892020 cites W3187060400 @default.
• W4294892020 doi "https://doi.org/10.1200/jco.22.00291" @default.
• W4294892020 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36070540" @default.
• W4294892020 hasPublicationYear "2023" @default.
• W4294892020 type Work @default.
• W4294892020 citedByCount "23" @default.
• W4294892020 countsByYear W42948920202022 @default.
• W4294892020 countsByYear W42948920202023 @default.
• W4294892020 crossrefType "journal-article" @default.
• W4294892020 hasAuthorship W4294892020A5001186013 @default.
• W4294892020 hasAuthorship W4294892020A5007373031 @default.
• W4294892020 hasAuthorship W4294892020A5012009133 @default.
• W4294892020 hasAuthorship W4294892020A5028075025 @default.
• W4294892020 hasAuthorship W4294892020A5034012906 @default.
• W4294892020 hasAuthorship W4294892020A5039245628 @default.
• W4294892020 hasAuthorship W4294892020A5039736511 @default.
• W4294892020 hasAuthorship W4294892020A5044655732 @default.
• W4294892020 hasAuthorship W4294892020A5062258178 @default.
• W4294892020 hasAuthorship W4294892020A5071527937 @default.
• W4294892020 hasAuthorship W4294892020A5078818153 @default.
• W4294892020 hasAuthorship W4294892020A5080149644 @default.
• W4294892020 hasAuthorship W4294892020A5080722354 @default.
• W4294892020 hasAuthorship W4294892020A5087302565 @default.
• W4294892020 hasConcept C121608353 @default.
• W4294892020 hasConcept C126322002 @default.
• W4294892020 hasConcept C141071460 @default.
• W4294892020 hasConcept C143998085 @default.
• W4294892020 hasConcept C197934379 @default.
• W4294892020 hasConcept C2780306303 @default.
• W4294892020 hasConcept C2780427987 @default.
• W4294892020 hasConcept C2780580376 @default.
• W4294892020 hasConcept C2781100745 @default.
• W4294892020 hasConcept C2781167935 @default.
• W4294892020 hasConcept C31174226 @default.
• W4294892020 hasConcept C71924100 @default.
• W4294892020 hasConcept C96232424 @default.
• W4294892020 hasConceptScore W4294892020C121608353 @default.
• W4294892020 hasConceptScore W4294892020C126322002 @default.
• W4294892020 hasConceptScore W4294892020C141071460 @default.
• W4294892020 hasConceptScore W4294892020C143998085 @default.
• W4294892020 hasConceptScore W4294892020C197934379 @default.
• W4294892020 hasConceptScore W4294892020C2780306303 @default.
• W4294892020 hasConceptScore W4294892020C2780427987 @default.
• W4294892020 hasConceptScore W4294892020C2780580376 @default.
• W4294892020 hasConceptScore W4294892020C2781100745 @default.
• W4294892020 hasConceptScore W4294892020C2781167935 @default.
• W4294892020 hasConceptScore W4294892020C31174226 @default.
• W4294892020 hasConceptScore W4294892020C71924100 @default.
• W4294892020 hasConceptScore W4294892020C96232424 @default.
• W4294892020 hasIssue "2" @default.
• W4294892020 hasLocation W42948920201 @default.
• W4294892020 hasLocation W42948920202 @default.
• W4294892020 hasOpenAccess W4294892020 @default.
• W4294892020 hasPrimaryLocation W42948920201 @default.
• W4294892020 hasRelatedWork W2112579958 @default.
• W4294892020 hasRelatedWork W2354785620 @default.

• next